Jeanette, what do you think about this? Like, do you, you know, do you immediately go from a TNF to a JAK or perhaps a different mechanism of action? Or do you stick with it?

Yeah, I think...

First of all, were they, you know, the primary responder versus second or non-responder versus a secondary non-responder? I think in this study, I'm looking at it now, the majority of the patients were primary non-responders.

So that means they really didn't, let's just talk about Entanercept, for instance, really didn't respond to that drug within the timeframe in which we would expect rather than it sort of petering out over time.

or disease busting through.

So I think that that's interesting.

Historically in my practice, if a patient was a primary non-responder, I would have definitely switched mechanism of action.

Jeanette, is there anything else that you would add when you're like talking to patients about switching from a TNF to a JAK?